Benfotiamine and Diabetic Neuropathy
Benfotiamine is aimed at a different target from everything else in this section. It is not trying to lower your blood sugar. It is trying to reduce the damage that high blood sugar causes — specifically through the advanced glycation pathway that injures nerves.
Evidence tier 2, and the most recent trial was negative.
Table of Contents
A Fat-Soluble Thiamine
Thiamine (vitamin B1) is water-soluble and its absorption is saturable, which caps how much can be pushed into tissue. Benfotiamine is a synthetic S-acyl derivative that is lipid-soluble and reaches substantially higher tissue thiamine concentrations than an equivalent dose of thiamine itself.
The reason to want that: thiamine is the cofactor for transketolase, an enzyme that diverts excess glycolytic intermediates into the pentose phosphate pathway. When glucose is high, those intermediates accumulate and feed four damaging routes — the polyol pathway, hexosamine pathway, protein kinase C activation, and formation of advanced glycation end products. Boosting transketolase is meant to drain the pool before it does harm.
This is a genuinely elegant mechanism and it targets the complication rather than the cause — the same strategic position as alpha-lipoic acid occupies.
The 12-Month Trial
Ziegler and colleagues published a 12-month randomised trial of benfotiamine in type 2 diabetes with polyneuropathy in BMJ Open Diabetes Research & Care in 2026. Fifty-seven participants were randomised, and the primary outcome — change in corneal nerve fibre length, an objective structural measure of small-fibre nerve damage — did not differ between the benfotiamine and placebo groups. The secondary morphometric, neurophysiological, clinical and quality-of-life outcomes did not differ either.
That is a clean negative result on the outcome that matters most, from the same research group that produced much of the positive alpha-lipoic acid evidence. It deserves more weight than the shorter, smaller, symptom-score studies that preceded it, because structural nerve measures are harder to move and harder to fool than a patient-reported symptom scale.
Mandra and colleagues' 2026 review and meta-analysis of B-vitamin supplementation for diabetic peripheral neuropathy in the Journal of Clinical Medicine sets the broader context.
Where That Leaves It
Benfotiamine is well tolerated and inexpensive, and the mechanism remains scientifically interesting. But a well-conducted 12-month trial with an objective structural endpoint found nothing, and honest reporting means leading with that rather than burying it under the mechanism.
For diabetic neuropathy specifically, the intervention with the better evidence is alpha-lipoic acid, which is a licensed medicine for this indication in Germany. And the intervention with better evidence than either is glucose control itself.
Cautions
- It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
- Do not let a supplement delay a neuropathy work-up. Numb or burning feet have several causes, some of which are urgent and none of which are diagnosed by trying benfotiamine.
- Thiamine deficiency is a separate, real condition in heavy drinkers and after bariatric surgery, and it is treated with thiamine under medical supervision, not with a supplement chosen for neuropathy.
- Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes with polyneuropathy. BMJ Open Diabetes Research & Care, 2026;14(1):e005773. Negative on the primary and secondary outcomes.
- Mandra, et al. Vitamin B Supplementation for Diabetic Peripheral Neuropathy: A Review and Meta-Analysis. Journal of Clinical Medicine, 2026;15(13):5156.